An article from
News roundup
Some analysts believe Silence’s polycythemia vera drug could be superior to a closely watched Takeda medicine. Elsewhere, the FDA spurned a would-be competitor to Novartis’ Lutathera.
Published Aug. 12, 2026
Getty Images
Silence cashes in on ‘differentiated’ data; UK reaffirms support for childhood vaccines
Some analysts believe Silence’s polycythemia vera drug could be superior to a closely watched Takeda medicine. Elsewhere, the FDA spurned a radiopharmaceutical and AbCellera shares climbed to levels not seen since 2023.
608 words~3 min read
